Peptides of il1 beta and tnf alpha and method of treatment...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 38/04 (2006.01) A61K 38/08 (2006.01) A61K 38/10 (2006.01) C07K 14/00 (2006.01)

Patent

CA 2557654

The present invention relates to peptides derived from the proinflammatory cytokines, interleukin-1~, (IL1~) and tumor necrosis factor .alpha., (TNF.alpha.), and their use in human or veterinary therapy, such as to generally treat diseases linked to the overproduction of IL1~ or TNF.alpha. as well as acute or chronic inflammatory diseases, rheumatoid arthritis, septic shock, autoimmune diabetes, graft rejection in the host, etc.

L'invention concerne des peptides dérivés des cytokines proinflammatoires, de l'interleukine-1ß, (IL1ß), et du facteur de nécrose des tumeurs .alpha., (TNF.alpha.), et l'utilisation de ces peptides pour les traitements thérapeutiques de patients humains et animaux, notamment le traitement de maladies associées à un surproduction d'IL1ß ou de TNF.alpha., ainsi que des maladies inflammatoires aiguës ou chroniques, de la polyarthrite rhumatoïde, des chocs septiques, du diabète autoimmun, des rejets de greffes par l'hôte etc.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Peptides of il1 beta and tnf alpha and method of treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides of il1 beta and tnf alpha and method of treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides of il1 beta and tnf alpha and method of treatment... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1700851

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.